What this trial means for you
This study is active, not recruiting — it is not currently taking new participants, but its results may matter for treatments you're considering. It's studying Glucagon-Like Peptide- 1 (GLP-1) infusion for type 2 diabetes mellitus.
What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study — ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.
The study, in the sponsor's words
Low blood sugar can negatively affect how blood vessels function, and this can lead to an increase in the risk for heart attacks, strokes and other problems related to the stiffening and blockage of blood vessels. The purpose of this study is to learn if and how glucagon-like peptide-1 (GLP-1; a naturally occurring hormone in the gut) changes the effects that low blood sugar levels have on blood vessels.
Can you join? The exact criteria
Below is the verbatim eligibility text from the registry — bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.
Full eligibility criteria (for you and your doctor)
Inclusion Criteria: * 14 (7 males, 7 females) healthy controls age 30-60 yr. * 14 (7 males, 7 females) people with type 2 DM age 30-60 yr. * For type 2 DM: HbA1c 6-10.0% * No significant diabetic tissue complications (i.e. history of retinopathy, neuropathy, stasis ulcers, etc.) * Body mass index \>25kg • m-2 Exclusion Criteria: \-
Study sites by state
Maryland
- University of Maryland, Baltimore — Baltimore
View the official record on ClinicalTrials.gov →
Follow this trial
Get an email when our monthly digest covers enrollment changes and results for trials like this one.
Newsletter signup launches soon. (Site owner: set PUBLIC_BUTTONDOWN_USERNAME in
.env to activate this form.)